a study relating to the utility of contrast enhanced EUS with sonazoid for diagnose of hepato-pancreato-biliary disease.

a study relating to the utility of contrast enhanced EUS with sonazoid for diagnose of hepato-pancreato-biliary disease. - a study relating to the utility of contrast enhanced EUS with sonazoid for diagnose of hepato-pancreato-biliary disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008488

Enrollment

400

Registered

2012-07-20

Start date

2012-02-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All indication cases for ceEUS

Interventions

sonazoid 0.01ml/Kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All indication cases for ce-EUS

Exclusion criteria

Exclusion criteria: Patients without written informed consent Patients with severely impaired organ function Patients considered ineligible for this study Patients with allergy for sonazoid Patients with allergy for egg Patients with possibility of pregnant

Design outcomes

Primary

Measure	Time frame
diagnostic capability	—

Secondary

Measure	Time frame
Lesion detectability, amounts of medicine	—

Countries

Japan

Contacts

Public ContactAshida Reiko

Osaka Medical Center for Cancer and Cardiovascular Diseases Departments of Cancer Survey and Gastrointestinal Oncology

asida-re@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026